Literature DB >> 26996978

Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?

Sandrine Faivre1,2, Armand de Gramont3, Eric Raymond4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26996978     DOI： 10.1007/s11523-016-0427-8

Source DB:  PubMed          Journal:  Target Oncol        ISSN： 1776-2596            Impact factor:   4.493


× No keyword cloud information.
  13 in total

Review 1.  Hepatocellular carcinoma: reasons for phase III failure and novel perspectives on trial design.

Authors:  Josep M Llovet; Virginia Hernandez-Gea
Journal:  Clin Cancer Res       Date:  2014-03-03       Impact factor: 12.531

2.  The anti-viral effect of sorafenib in hepatitis C-related hepatocellular carcinoma.

Authors:  R Cabrera; A R Limaye; P Horne; R Mills; C Soldevila-Pico; V Clark; G Morelli; R Firpi; D R Nelson
Journal:  Aliment Pharmacol Ther       Date:  2012-10-24       Impact factor: 8.171

Review 3.  Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.

Authors:  Brett E Houk; Carlo L Bello; Bill Poland; Lee S Rosen; George D Demetri; Robert J Motzer
Journal:  Cancer Chemother Pharmacol       Date:  2009-12-05       Impact factor: 3.333

4.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Zhendong Chen; Chao-Jung Tsao; Shukui Qin; Jun Suk Kim; Rongcheng Luo; Jifeng Feng; Shenglong Ye; Tsai-Sheng Yang; Jianming Xu; Yan Sun; Houjie Liang; Jiwei Liu; Jiejun Wang; Won Young Tak; Hongming Pan; Karin Burock; Jessie Zou; Dimitris Voliotis; Zhongzhen Guan
Journal:  Lancet Oncol       Date:  2008-12-16       Impact factor: 41.316

5.  The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer.

Authors:  A R Feinstein; D M Sosin; C K Wells
Journal:  N Engl J Med       Date:  1985-06-20       Impact factor: 91.245

6.  Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.

Authors:  Philip J Johnson; Shukui Qin; Joong-Won Park; Ronnie T P Poon; Jean-Luc Raoul; Philip A Philip; Chih-Hung Hsu; Tsung-Hui Hu; Jeong Heo; Jianming Xu; Ligong Lu; Yee Chao; Eveline Boucher; Kwang-Hyub Han; Seung-Woon Paik; Jorge Robles-Aviña; Masatoshi Kudo; Lunan Yan; Abhasnee Sobhonslidsuk; Dmitry Komov; Thomas Decaens; Won-Young Tak; Long-Bin Jeng; David Liu; Rana Ezzeddine; Ian Walters; Ann-Lii Cheng
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Deng-Yn Lin; Joong-Won Park; Masatoshi Kudo; Shukui Qin; Hyun-Cheol Chung; Xiangqun Song; Jianming Xu; Guido Poggi; Masao Omata; Susan Pitman Lowenthal; Silvana Lanzalone; Liqiang Yang; Maria Jose Lechuga; Eric Raymond
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

9.  Exposure-toxicity relationship of sorafenib in Japanese patients with renal cell carcinoma and hepatocellular carcinoma.

Authors:  Masahide Fukudo; Takuma Ito; Tomoyuki Mizuno; Keiko Shinsako; Etsuro Hatano; Shinji Uemoto; Tomomi Kamba; Toshinari Yamasaki; Osamu Ogawa; Hiroshi Seno; Tsutomu Chiba; Kazuo Matsubara
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

Review 10.  Incidence and risk of sorafenib-induced hypertension: a systematic review and meta-analysis.

Authors:  Yan Li; Shun Li; Yaofeng Zhu; Xinyue Liang; Hui Meng; Jun Chen; Dongqing Zhang; Hu Guo; Benkang Shi
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-03       Impact factor: 3.738
View more
  3 in total

Review 1.  Sorafenib: A Review in Hepatocellular Carcinoma.

Authors:  Gillian M Keating
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.864

Review 2.  Targeting Lymphangiogenesis and Lymph Node Metastasis in Liver Cancer.

Authors:  Sukanya Roy; Priyanka Banerjee; Burcin Ekser; Kayla Bayless; David Zawieja; Gianfranco Alpini; Shannon S Glaser; Sanjukta Chakraborty
Journal:  Am J Pathol       Date:  2021-09-09       Impact factor: 4.307

Review 3.  Emerging agents and regimens for hepatocellular carcinoma.

Authors:  Xiao-Dong Zhu; Hui-Chuan Sun
Journal:  J Hematol Oncol       Date:  2019-10-26       Impact factor: 17.388
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.